Health

Thrombosis Drugs Market To Evolve In Near Future 2026

Press Release

Global Thrombosis Drugs Market – Snapshot

Thrombosis is the medical term for an abnormal blood clot in an artery or vein. Thrombosis drugs are used to prevent or treat the blood clot, which can cause different thrombotic events. Medication to treat is likely to include anticoagulants drugs and thrombin inhibitors drugs. In terms of revenue, the global thrombosis market was valued at approximately US$ 20,000 Mn in 2017 and is anticipated to surpass US$ 47,000 Mn by 2026, expanding at a CAGR of 9.5% from 2018 to 2026. Rise in the number of patients affected by thrombosis and availability of new drugs formulation products with improved features are likely to fuel the global thrombosis drugs market from 2018 to 2026.

View Report: https://www.transparencymarketresearch.com/thrombosis-drugs-market.html

Thrombosis drugs are generally blood thinners. These drugs decrease the clotting power of blood and consequently, the chances of thrombosis events, such as pulmonary embolism, decrease. These drugs are available in the form of injection, capsule, and tablet. Key players are focusing on the development of drugs with better efficacy. For instance, Grifols Therapeutics Inc., a U.S.-based biotechnology company is projected to launch AT- lll, a new type of human recombinant thrombosis drugs for the indication of cardiac surgery cardiopulmonary bypass. Such key developments are likely to fuel the global thrombosis drugs market in the near future. However, the high price of non-vitamin K oral anticoagulant drugs and the availability of generic drugs are likely to hamper the global thrombosis drugs market during the forecast period.

Several unmet needs are anticipated to create significant opportunities for existing players and new entrants in the global thrombosis drugs market. Rapid technological advancements in treatment therapies create opportunities for players operating in the global thrombosis drugs market. Ongoing developments in thrombosis drugs, such as Revo Biologic’s ATryn with continuous infusion of drugs are likely drive the thrombosis drugs market during the forecast period.

Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=46293

The global thrombosis drugs market can be segmented based on drug class, indication, distribution channel, and geography. In terms of drug class, the factor Xa inhibitor segment dominated the market and is expected to continue this trend during the forecast period, followed by the P2Y12 platelet inhibitor segment. Increasing preference for the usage of oral anticoagulant drugs with predictable dose release response is likely to propel the segment during the forecast period. The low molecular weight heparin drug class segment, is likely to lose market share during the forecast period owing to patent expiry. Based on indication, the pulmonary embolism segment led the market, in terms of revenue, in 2017. The segment is projected to continue to dominate the market during the forecast period. In terms of distribution channel, the hospital pharmacies segment accounted for a large share of the market in 2017 and is likely to continue its dominance during the forecast period.

In terms of geography, North America held a major share of the global thrombosis drugs market in 2017. High utilization rate of new oral anticoagulant drugs is a key factor that propels the market in North America. Moreover, favorable reimbursement for the treatment of different thrombosis events under Medicare policy also boosts the market in this region. In terms of revenue, the market in Europe and Asia Pacific is projected to expand during the forecast period. Rising prevalence of deep vein thrombosis and increasing awareness about the treatment and usage of drugs to treat different thrombosis events in countries such as Brazil and South Africa are likely to boost the market in Latin America and Middle East & Africa.

Request a Sample of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=46293

Key companies operating in the global thrombosis drugs market, which are profiled in the report, include GlaxoSmithKline plc., Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Bayer AG, Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH, and Pfizer, Inc. These players are adopting organic and in-organic growth strategies to expand their product offerings, strengthen their geographical reach, increase customer base, and gain market share. For instance, in September 2014, Mylan Inc., acquired the U.S. commercialization, marketing, and intellectual property rights relating to Arixtra (fondaparinux sodium) injection and the authorized generic of Arixtra from Aspen Global Incorporated. This acquisition enhanced Mylan Inc’s expansion opportunities in the U.S. market.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us

Transparency Market Research

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: [email protected]

Website: https://www.transparencymarketresearch.com

This post was originally published on The Market Plan